Literature DB >> 10866325

Arginase activity in human breast cancer cell lines: N(omega)-hydroxy-L-arginine selectively inhibits cell proliferation and induces apoptosis in MDA-MB-468 cells.

R Singh1, S Pervin, A Karimi, S Cederbaum, G Chaudhuri.   

Abstract

L-Arginine is the common substrate for two enzymes, arginase and nitric oxide synthase (NOS). Arginase converts L-arginine to L-ornithine, which is the precursor of polyamines, which are essential components of cell proliferation. NOS converts L-arginine to produce NO, which inhibits proliferation of many cell lines. Various human breast cancer cell lines were initially screened for the presence of arginase and NOS. Two cell lines, BT-474 and MDA-MB-468, were found to have relatively high arginase activity and very low NOS activity. Another cell line, ZR-75-30, had the highest NOS activity and comparatively low arginase activity. The basal proliferation rates of MDA-MB-468 and BT-474 were found to be higher than the ZR-75-30 cell line. N-Hydroxy-L-arginine (NOHA), a stable intermediate product formed during conversion of L-arginine to NO, inhibited proliferation of the high arginase-expressing MDA-MB-468 cells and induced apoptosis after 48 h. NOHA arrested these cells in the S phase, increased the expression of p21, and reduced spermine content. These effects of NOHA were not observed in the ZR-75-30 cell line, which expresses high NOS and relatively low arginase. The effects of NOHA were antagonized in the presence of L-ornithine (500 microM), which suggests that in MDA-MB-468 cell line, the arginase pathway is very important for cell proliferation. Inhibition of the arginase pathway led to depletion of intracellular spermine and apoptosis as observed by terminal deoxynucleotidyl transferase (Tdt)-mediated nick end labeling assay and induction of caspase 3. In contrast, the ZR-75-30 cell line maintained its viability and its L-ornithine and spermine levels in the presence of NOHA. We conclude that NOHA has antiproliferative and apoptotic actions on arginase-expressing human breast cancer cells that are independent of NO.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10866325

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  59 in total

Review 1.  Recent advances in arginine metabolism: roles and regulation of the arginases.

Authors:  Sidney M Morris
Journal:  Br J Pharmacol       Date:  2009-06-05       Impact factor: 8.739

2.  Classification of Homo sapiens gene behavior using linear discriminant analysis fused with minimum entropy mapping.

Authors:  Joyshri Das; Soma Barman Mandal
Journal:  Med Biol Eng Comput       Date:  2021-02-17       Impact factor: 2.602

3.  Binding of α,α-disubstituted amino acids to arginase suggests new avenues for inhibitor design.

Authors:  Monica Ilies; Luigi Di Costanzo; Daniel P Dowling; Katherine J Thorn; David W Christianson
Journal:  J Med Chem       Date:  2011-07-18       Impact factor: 7.446

Review 4.  Pharmacokinetics and Pharmacodynamics of Promising Arginase Inhibitors.

Authors:  Khaled S Abdelkawy; Kelsey Lack; Fawzy Elbarbry
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2017-06       Impact factor: 2.441

5.  2-aminoimidazole amino acids as inhibitors of the binuclear manganese metalloenzyme human arginase I.

Authors:  Monica Ilies; Luigi Di Costanzo; Michelle L North; Jeremy A Scott; David W Christianson
Journal:  J Med Chem       Date:  2010-05-27       Impact factor: 7.446

6.  Nitric oxide-induced cytostasis and cell cycle arrest of a human breast cancer cell line (MDA-MB-231): potential role of cyclin D1.

Authors:  S Pervin; R Singh; G Chaudhuri
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-13       Impact factor: 11.205

7.  Elucidating the Electrochemical Mechanism of NG-Hydroxy-L-arginine.

Authors:  Mariah L Arral; Christian Tooley; Emily Ziino; Jeffrey Mark Halpern
Journal:  J Electrochem Soc       Date:  2020-01-09       Impact factor: 4.316

8.  Polyarginine molecular weight determines transfection efficiency of calcium condensed complexes.

Authors:  Nabil A Alhakamy; Cory J Berkland
Journal:  Mol Pharm       Date:  2013-04-15       Impact factor: 4.939

Review 9.  Endogenous morphine/nitric oxide-coupled regulation of cellular physiology and gene expression: implications for cancer biology.

Authors:  George B Stefano; Richard M Kream; Kirk J Mantione; Melinda Sheehan; Patrick Cadet; Wei Zhu; Thomas V Bilfinger; Tobias Esch
Journal:  Semin Cancer Biol       Date:  2007-12-08       Impact factor: 15.707

Review 10.  Arginine depriving enzymes: applications as emerging therapeutics in cancer treatment.

Authors:  Neha Kumari; Saurabh Bansal
Journal:  Cancer Chemother Pharmacol       Date:  2021-07-26       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.